Dutch generic drugmaker Mylan said that the US District Court for the Northern District of West Virginia has invalidated Biogen’s Tecfidera patent U.S. Patent No. 8,399,514 for lack of written description. According to the company, the 8,399,514 patent claimed methods for the treatment of multiple sclerosis (MS) with a dose of 480 mg/day of dimethyl […]
Mylan and Biocon have secured approval from the US Food and Drug Administration (FDA) for Semglee (insulin glargine injection) in vial and pre-filled pen presentations to regulate high blood sugar in adults with type 2 diabetes and adult and pediatric patients with type 1 diabetes. According to Mylan, Semglee has an identical amino acid sequence […]
